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Abstract 
Flucloxacillin (FLU) administered by the oral route is widely used for treating various infections, but 
there are no published retrospective or prospective trials of its efficacy, or its advantages or 
disadvantages compared to parenteral treatment or other antibiotics for treating osteomyelitis. 
Based on published in vitro data and expert opinions, other non-β-lactam oral antibiotics that have 
better bone penetration are generally preferred over oral FLU. We reviewed the literature for 
studies of oral FLU as therapy of osteomyelitis (OM), stratified by acute versus chronic and pediatric 
versus adult cases. In striking contrast to the prevailing opinions and the few descriptive data 
available, we found that treatment of OM with oral FLU does not appear to be associated with more 
clinical failures compared to other oral antibiotic agents. Because of its narrow antibiotic spectrum, 
infrequent severe adverse effects, and low cost, oral FLU is widely used in clinical practice. We 
therefore call for investigators to conduct prospective trials investigating the effectiveness and 
potential advantages of oral FLU for treating OM. 
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Introduction 
The traditional antibiotic regimen for a patient 
who has undergone surgical debridement for 
osteomyelitis (OM) includes 2-6 weeks of parenterally 
administered agent(s), followed by an oral course of 
several weeks (1,2). Parenteral (usually intravenous) 
antibiotic therapy is associated with several 
substantial problems: it requires either prolonged 
hospitalization or treatment by an outpatient 
parenteral antibiotic therapy (OPAT) unit; the 
required intravenous catheter (usually a central line) 
is associated with frequent adverse effects (including 
infection and thrombosis); and, it is associated with 
high financial costs. For example, an evaluation by 
Gardiol et al. (3) of their OPAT program in 
Switzerland found that 16 of their 179 (9 %) OPAT 
patients had complications associated with the 
treatment. The most common were drug-related 
adverse events, which occurred in ten patients (5.5 %) 
and required readmission to the hospital in three 
cases. There were also six line-related (all peripheral) 
adverse events (3.5 %) (3). 
Flucloxacillin (FLU) is a narrow-spectrum, 
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semisynthetic penicillin available in both parenteral 
and oral formulations (4-8). It is active against aerobic 
gram-positive pathogens, notably including 
methicillin-susceptible Staphylococcus aureus (MSSA) 
(8). FLU is closely related to other semisynthetic 
penicillins (nafcillin, oxacillin, (di)cloxacillin) that 
have been widely used for decades for a variety of 
orthopedic and community-acquired skin infections 
worldwide (8,9). Treatment with FLU has several 
theoretical advantages over other antibiotic agents for 
these infections: it has bactericidal properties 
(potentially important for selected infections); its 
antibiotic spectrum is limited (reducing risk of 
antibiotic resistance); it is inexpensive (reducing 
financial costs); and the two formulations afford the 
possibility of an early switch from intravenous to oral 
dosing (reducing risks and potentially allowing 
earlier hospital discharge) (6). One potentially 
challenging issue is that the bone penetration of oral 
β-lactam antibiotics, at least in vitro, is poor (4-7). 
Unfortunately, there are almost no published clinical 
data on the effectiveness or safely of treatment with 
oral FLU for osteomyelitis (OM).  
This lack of evidence of the usefulness of oral 
semi-synthetic antibiotic agents has led to 
international expert groups and guidelines, such as 
the Infectious Diseases Society of America (IDSA) 
guidelines (9) and the European Society for Pediatric 
Infectious Diseases (ESPID) (10) to recommend that 
the preferred route of administration for treating OM 
are intravenous FLU or a first-generation 
cephalosporin (9,10). Nevertheless, clinicians in some 
countries with a low endemicity of 
methicillin-resistant S. aureus isolates, e.g., the Nordic 
countries, Baltic States and Netherlands, use oral FLU, 
at least for the maintenance therapy, of staphylococcal 
OM (6). Several recent studies have demonstrated that 
oral β-lactam antibiotics, e.g. co-amoxiclav, can be 
safely used in many types of bone and joint infections, 
including for diabetic foot OM (11). In the United 
Kingdom, the prescribing of oral FLU has increased 
by 21% during the past decade (12), and oral FLU can 
be used for OM (13). Considering the potential 
benefits, and lack of published data, we present this 
narrative review to address the potential place of oral 
FLU for treating OM. 
Methods 
We performed a narrative literature review by 
searching for articles in PubMed (using the MeSH 
terms “oral flucloxacillin”, “Staphylococcus aureus” and 
“osteomyelitis”), Google Scholar and references cited 
in retrieved articles. We reviewed articles written in 
English; with correspondence in German, French, 
Romanian and Turkish languages. Our review only 
sought papers concerned with oral FLU for treating 
MSSA infections, not those on intravenous 
formulations or for treatment of other bacteria. For 
our inclusion criteria we defined that the duration of 
oral FLU used in the study must be more than the half 
of the total antibiotic course. We did not consider 
antibiotic dosing of oral FLU considerations or 
minimal clinical follow-up time of enrolled patients as 
inclusion criteria. We excluded studies: on animals; 
using combination therapies with oral rifampin; 
reporting on infected implants or soft tissue 
infections; on virulence analyses (14); on  S. aureus 
body carriage or colonization (15); on 
pharmacokinetic-pharmacodynamics (PK/PD) issues 
(16); or, on minimal inhibitory concentration (MIC) 
assessments (17,18). We also excluded papers 
predominatingly related to only related antibiotic 
regimens, such as nafcillin, oxacillin, or 
(di)-cloxacillin. Additionally, we explored data on the 
levels of oral FLU use in Switzerland during the past 
decade.  
Results 
General results of the literature search 
Our review produced 420 articles, only 58 of 
which met our criteria and we used these to 
synthetize our review. Papers with own clinical cases 
of oral FLU use in OM are analyzed more in detail 
(Figure 1). We stratified them as involving childhood 
or adult OM cases, acute or chronic OM cases, and 
between case reports and case series (Tables 1-5). 
Although many of the included papers provided 
information on the feasibility of oral FLU therapy for 
OM, this was not the underlying primary issue of any. 
As the heterogeneity and the large amount of missing 
information in the papers were so great, we could not 
attempt any type of meta-analyses of our results. Of 
note, most of the studies were conducted in English 
speaking (particularly the United Kingdom) and 
Nordic countries. 
Authority recommendations for prescription 
of oral flucloxacillin in Switzerland 
According to the most frequently used Swiss 
Federal documentation (40), general indications for 
treatment with FLU are the same as in most other 
countries: skin and soft tissue infections, infection 
with MSSA, susceptible coagulase-negative 
staphylococci, as well as streptococci and other 
non-staphylococcal gram-positive bacteria (albeit as a 
weak recommendation). Importantly, they do not specify 
if the route of administration routes should be 
different for bone than for soft tissue infections. 
Among Swiss Infectious Diseases physicians, treating 
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with oral FLU for OM is unpopular for the treatment 
of OM (personal communications). One example of a 
related consequence is that in Switzerland, because 
prospective trials involving use of oral antibiotic 
therapy must pass through the Ethical Committees, 
researchers avoid using oral FLU as a therapeutic 
option for studies of bone and joint infections (41). 
This is not the same in other countries (42). For 
example, in Sweden, Fiji and Australia, oral FLU can 
be officially used for studies of treatment of OM 
(43-46).  
Official prices and registered use of oral 
flucloxacillin in Switzerland 
The daily price for treatment with oral FLU (500 
mg, 3-4 times a day) on the Swiss market is five Swiss 
Francs ($5 US dollars in October 2019). The quantity of 
oral FLU prescribed in Switzerland between 2004 and 
2017 was 0.13 DDD (defined daily dose) per 1000 
patient-months. There was a two-fold increase in use 
during this time period in the French-speaking part of 
the country, a 29% increase in the Italian-speaking 
part, and an 18% in the German-speaking majority 
regions (ANRESIS databases; 47). In our Balgrist 
University Hospital, a referral center for orthopedic 
infections, the corresponding DDD was 0.72 per 1000 
patient-months in 2017. In comparison, in the United 
Kingdom (the country with the most publications 
regarding oral FLU in OM), the average monthly 
prescription rates increased from 4.74 per 1000 
patient-months in 2004 to 5.74 in 2013, an increase of 
21.1% (12). We do not know the reasons for this 
increase in prescribing of oral FLU, but it might be 
that British physicians chose to prescribe more of the 
500 mg tablets the 250 mg capsules (12). In Sweden, 
the usual daily dosing of oral FLU is 1.5 g three times 
daily for OM and septic arthritis (44). The EUCAST 
Clinical Breakpoint Tables (European dosing 
recommendations) promote a “standard dose” of oral 
FLU of 1.0 g three times daily; and a “high oral dose” 
of 1g four times daily in some cases (48). 
International guidelines 
To our knowledge, treatment with oral FLU is 
not a primary choice for OM in any internationally 
accepted guidelines. For example, the ESPID 
guidelines (10) recommend initial therapy with a 1st or 
2nd generation cephalosporin (for other susceptible 
bacteria other than MSSA). For treating adult in the 
OM population, the IDSA guidelines (9) advocate 
1.5-2.0 g of intravenous oxacillin (the nearest 
equivalent to flucloxacillin) every four hours. Both 
guidelines consider almost all other oral β-lactams, as 
a group and independently of their dosing, 
inappropriate due to poor bone penetration in vitro 
(with the possible exception or amoxicillin and 
co-amoxiclav in certain circumstances); this is true 
even when the patient has shown a good response to 
initial parenteral therapy treatment with a 
non-preferred agent. In striking contrast, after a 
favorable clinical response to parenteral treatment, 
guidelines encourage switching to oral antibiotic 
classes for almost all other agents (e.g., quinolones, 
linezolid, clindamycin, co-trimoxazole, tetracyclines, 
 
Figure 1: Review flowchart 
 
 J. Bone Joint Infect. 2020, Vol. 5 
 
http://www.jbji.net 
19 
and metronidazole) provided there is (9). The failure 
to recommend oral FLU also applies for DFO in the 
US guidelines (49). 
Regional and national recommendations 
In contrast to their international counterparts, 
many national guidelines explicitly recommend 
treatment with oral FLU for MSSA OM, generally 
citing the favorable personal experience of the author 
groups (12). A UK study reported that general 
practitioners treated 394 OM episodes at least 
partially with oral FLU, with generally favorable 
results (12). Recent recommendations from South 
Korea also mention the possibility of post-surgical 
treatment of OM with oral FLU (50). Swedish (44), 
Australian (46) and Fijian (45) guidelines also support 
treatment with oral FLU in OM, including 
spondylodiscitis (44). Similarly, the national 
Australian Antibiotic Guidelines (Therapeutic 
Guidelines) promote oral FLU as a first line treatment 
for acute and chronic OM, albeit following a 2-4 week 
course of intravenous FLU (46). 
Published clinical efficacy of oral flucloxacillin 
in osteomyelitis 
Tables 1-5 present summaries of the published 
clinical literature on treatment of OM with oral FLU. 
Over twenty years ago Lowden et al. reported that 
among five children with clavicular OM (19) four 
(80%) relapsed after three weeks intravenous FLU 
followed by three to four weeks of oral FLU. The 
author`s attributed this high recurrence rate to the 
clavicle being a difficult anatomic site to treat. No 
subsequent studies have reported such a high failure 
rate, suggesting there may have been other problems 
in the management of these patients (19). Vinod et al. 
reported their experience with children treated for 
OM or septic arthritis (20). In 77% of the cases the 
children received intravenous FLU followed by oral 
FLU. Overall, the recurrence rate was only 1.4%, 
demonstrating the efficacy of oral FLU in treating 
hematogenous OM (20). Similarly, Nunn et al. 
demonstrated efficacy in the majority (exact numbers 
are not provided) of 43 evaluable children treated in 
an African hospital for OM with oral FLU following 
initial intravenous therapy (51). In 2001 Beronius et al. 
published their experience in Sweden of treating 42 
episodes of spondylodiscitis for a median of 10 days 
with intravenous antibiotics (cefuroxime in two-thirds 
of cases), followed by a median of 179 days of oral 
FLU, none of which were associated with a relapse 
(23). For the subset of patients with DFO, we found no 
well-designed trials comparing oral FLU with other 
antibiotic regimens. One study specifically comparing 
patients treated with oral β-lactam antibiotics to those 
treated with oral quinolones for DFO found no 
significant difference in the remission rates (52). 
Several case series, reports and surveys have 
demonstrated the feasibility of treatment with oral 
β-lactam therapy in DFO (3,36). Interestingly, a survey 
of Australasian infectious diseases clinicians found 
that oral FLU is the maintenance antibiotic treatment 
of choice, associated with good clinical responses, for 
staphylococcal DFO (53).  
In sum, the experience of the majority 
publications reporting on outcomes of treatment with 
oral FLU for OM have demonstrated good efficacy. 
While these studies used different dosing regimens 
and treatment durations, and had non-uniform rates 
of surgical treatment (Tables 1-5), many used oral FLU 
as a maintenance therapy after a course of initial 
parenteral antibiotic therapy. Among the reported 
cases series there were relatively few documented 
failures (Tables 1, 2 and 4). In one case, the authors 
treated a pediatric spondylodiscitis with oral FLU (27) 
and incriminate the relatively short duration of 
therapy (24 days), not the choice of FLU, as the cause 
of relapse. Other reported recurrences occurred in 
studies from New Zealand (31) and Denmark (36). 
Drug interactions and tolerability of oral 
flucloxacillin in the treatment of osteomyelitis 
Although comparative large epidemiological 
data are lacking, according to personal experience of 
various authors (personal communications) and 
published literature, oral FLU probably causes not 
more adverse events than other penicillins. The most 
common reported side effects include 
hypersensitivity, gastrointestinal symptoms, 
exanthema, nephrotoxicity, myelotoxicity, oxoproline 
acidosis. Drug-drug interactions have been reported 
with paracetamol (acetaminophen) (40,42), and rarely 
with warfarin is (54) and rifampin. In a study in 15 
adult patients with various osteoarticular infections 
(55) the combined treatment with intravenous FLU 
and oral rifampicin significantly increased serum FLU 
levels by 45% in 10 patients, while a decrease was 
observed in one patient. The clinical significance of 
this finding remained unknown, since all infections 
were cured (55). It is likely that oral FLU could also be 
associated with such an interaction, although possibly 
at a subclinical level. Contrary to common belief, it is 
probably not necessary to administer oral FLU on an 
empty stomach, as concomitant food intake does not 
appear to alter the pharmacokinetic parameters (56). 
One other interaction of note is that combining treated 
with FLU (like other penicillins) with probenecid 
commonly can boost the serum FLU concentrations 
(8,40,42). 
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Table 1 - Case series in humans of chronic osteomyelitis 
Reference, Year (Country) Patients,  Age IV treatment Duration of oral FLU Follow-up Outcome 
Lowden et al, 1997  
 (New Zealand)19 
5 patients 
7-8 years 
60% drainage 
21 days FLU IV 
21-42 days 0.5-1 year 80% relapse 
recovery not documented 
Vinod et al, 2001  
 (United Kingdom)20 
32 patients; 3 months  
to 16 years 
49% drainage 
IV therapy 3 days  
21-42 days  66% > 12 months 
34% < 12 months 
relapse rate 1.4% 
Sur et al, 2015  
 (United Kingdom)21 
55 patients 
26-96 years 
30% debridement 
40% FLU IV,  
24% vancomycin 
not known  not known not known 
Alonge et al, 2002  (Nigeria)22 3 patients not known 6 weeks not known no relapse 
Beronius et al, 2001  (Sweden)23 42 patients median 10 days 179 days not known no relapse  
FLU = Flucloxacillin; IV = intravenous. 
 
Table 2 - Case reports of treatment of children with acute osteomyelitis 
Reference, Year (Country) Pathogenesis Pathogen Treatment Surgery, IV antibiotic Duration of Oral FLU Outcome 
Hughes et al, 2016 
 (United Kingdom)24 
Hematogenous MSSA No operation 
FLU IV for 4 weeks 
14 days no relapse 
Pabla et al, 2011  
 (United Kingdom)25 
Traumatic Unknown No operation 
FLU & Penicillin IV 
64 days no relapse 
Chiappini et al, 2016  
 (Italy)26 
Microtrauma MSSA Drainage 
7 days ceftazidime IV 
28 days no relapse 
Dahal et al, 2019  
 (Nepal)27 
Spondylodiscitis MSSA 10 days vancomycin IV 14 days 1 relapse 
FLU = Flucloxacillin; IV = intravenous; MSSA = Methicillin-susceptible Staphylococcus aureus. 
 
Table 3 - Case reports of treatment of children with chronic osteomyelitis 
Study Pathogenesis Pathogen Treatment 
Surgery, IV antibiotic 
Duration of oral FLU Outcome 
El Mezouar et al, 2014  (Morocco)28 Trauma MSSA No operation 
FLU IV for 6 weeks 
120 days no relapse 
Freeman et al, 2008  
 (Malawi)29 
Trauma No culture Sequestrectomy; fibula transfer 
bone filling with gentamicin & vancomycin 
not known residual handicap 
no relapse 
Rajakulendran et al, 2013  
 (United Kingdom)30 
PIN-tract  
infection 
MSSA Not known 85 days no relapse 
Kerr et al, 2019  
 (United Kingdom)13 
Acetabular 
osteomyelitis 
MSSA Not known 28 days no relapse 
FLU = Flucloxacillin; IV = intravenous; MSSA = Methicillin-susceptible Staphylococcus aureus. 
 
Table 4 - Case reports of treatment of adults with acute osteomyelitis 
Study Pathogenesis Pathogen IV treatment  Duration of oral FLU Recovery 
Waterhouse et al, 2013 
(New Zealand)31 
Hematogenous MSSA, H. parainfluenzae 6 days Augmentin PO 
2 days FLU IV  
not known, long 1 relapse 
Cheer et al, 2009 (UK)32 Microtrauma MSSA 6 weeks FLU  not known, long No relapse 
Marshman et al, 2008 
(UK)33 
Hematogenous MSSA 12 days FLU IV 28 days No relapse 
Erturan et al, 2012 (UK)34 Hematogenous C. pseudodiphteriticium Synovectomy, 
8 days FLU IV 
8 days vancomycin IV 
42 days No relapse 
C. = Corynebacterium; FLU = Flucloxacillin; IV = intravenous; PO = orally; MSSA = Methicillin-susceptible Staphylococcus aureus 
 
Table 5 - Case reports of treatment of adults with chronic osteomyelitis 
Study Pathogenesis Pathogen IV treatment Duration of oral FLU Recovery 
Opara et al, 2007  
 (United Kingdom)35 
Hematogenous MSSA, TB 2 weeks FLU & Fusidic acid IV  
  
14 days 
42 days 
Residual handicap, no 
relapse 
One relapse 
Jeppesen et al, 2015    
 (Denmark)36 
Hematogenous MSSA No surgery 84 days No relapse 
Lindau et al, 2015  
 (United Kingdom)37 
Traumatic Not known Gentamicin beads 56 days No relapse 
Torda et al, 1995  
 (Australia)38 
Spondylodiscitis MSSA Not known 280 days No relapse 
Padala et al, 2013 (UK)39 Spondylodiscitis MSSA Fusidic acid 90 days No relapse 
FLU = Flucloxacillin; IV = intravenous; MSSA = Methicillin-susceptible Staphylococcus aureus; TB = Tuberculosis 
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Discussion 
Our review of the literature revealed that despite 
its widespread use around the world, there is 
remarkably little documentation of the clinical 
experience of treatment with oral FLU alone for the 
treatment of acute or chronic, implant-free, OM in 
children or adults. We found no randomized trials or 
retrospective multivariate analyses that adjusted for 
the large case-mix of included subjects.  
The few published reports of case series clearly 
reflect the personal experience of the authors, and are 
almost exclusively composed of case reports and 
small case series. The information on efficacy and 
adverse events if present at all, is largely hidden 
within the reports, as the primary objectives of the 
studies differed from those of our review.  
 Based on in vitro data, treatment with oral FLU 
(as with all oral β-lactam agents) warrants careful 
observation when used for treating OM. In most 
studies the ratios of bone to intravenous 
concentrations for β-lactams are about 5-20%, with a 
very wide inter-individual variation in the availability 
of oral FLU. As an example, the serum trough levels 
reported by Gath et al. were 15±5.9 mg/L (5), while 
the peak levels reported by Dijkmans et al were 22-26 
mg/L (range, 7-53 mg/L) (6). Thus, while most 
intravenous (and probably intramuscular) β-lactams 
reach the necessary MIC for MSSA in bone (57-61), 
this might not be the case with oral administration. 
One cause for the relatively low levels achieved with 
oral FLU is likely the innate variabilities in its 
gastrointestinal absorption (6). Among humans, 9% 
largely fail to absorb FLU and another 17% are poor 
absorbers (61). A pharmacologic in vivo study from 
the Netherlands (61) compared levels of cefuroxime 
and FLU when given by oral versus parenteral routes 
in plasma and intraoperative bone during twenty hip 
and knee arthroplasty surgeries. The authors 
allocated patients to four groups: either 1 x 500 mg or 
7 x 500 mg oral cefuroxime, following 2000 mg 
intravenous FLU; and either 1 x 500 mg or 7 x 500 mg 
oral FLU followed by 1500 mg parenteral cefuroxime. 
All oral administrations failed to achieve a 
measurable osseous concentration (60). FLU is a 
highly protein bound drug and it is predominantly 
the free drug that is active in the killing of bacteria. 
Even with a relatively high dosage of 1 g q.i.d, free 
plasma drug concentrations might drop below the 
MIC of a typical strain of MSSA (0.25 mg/l) at 50% of 
the dosing interval (56). Given a drug penetration into 
bone ratio of 10-20%, it is unlikely that a given dose of 
oral FLU will achieve therapeutic concentrations in 
the bone for several hours. We only found one 
published study reporting the contrary: Köndell et al. 
found a mandibular bone concentration of 3.8 mg/L 
after oral administration of FLU, which would likely 
be therapeutically adequate for treating MSSA OM 
(62).  
A key issue is that serum antibiotic concentration 
measurements do not reflect the entire pharmacologic 
picture, as it is not a highly predictable surrogate for 
the actual concentration of the administered antibiotic 
in infected bone (16). Likewise, information is lacking 
regarding the relationship between serum antibiotic 
concentrations over time and antibiotic effectiveness 
(time-over minimal inhibitory concentration [MIC]) 
for FLU and MSSA), as FLU is not an antibiotic that is 
peak concentration-dependent (as is true of all 
β-lactam antibiotics agents). Interested readers can 
review a paper in which members of our group 
recently summarized insights on the 
pharmacokinetic-pharmacodynamics of antibiotics in 
the bone (16). The effectiveness of antibiotic treatment 
for OM is complex, depending on the interaction of 
drug, host, microbial agent and other aspects. For 
example, it is disturbing that Alvarez-Ferrero et al. 
(61) failed to detect a measurable osseous 
concentration in vivo after administration of oral FLU, 
but they did not address the large technical and 
analytical problems in assessing drug concentrations 
in bone (61). There are likely also differences in 
antibiotic concentrations in cancellous versus cortical 
versus mixed homogenized bone, in infected versus 
non-infected bone, and issues related to blood 
contamination during bone sampling. Therapeutic 
drug monitoring (TDM) might be a solution to 
concerns about therapeutic concentration. In patients 
being treated with FLU use (oral or IV), several 
centers have introduced such TDM policies, but its 
clinical benefit remains unproven. Most TDM 
publications to date provide only laboratory (not 
clinical) data for FLU (63). This contrasts to antibiotics 
such as cefepime, for which TDM has been shown to 
help prevent potentially severe adverse events (64). 
The outcome of oral FLU treatment of OM does 
not appear to be worse than with other oral drugs (2), 
although direct comparative data are lacking. So, why 
does treatment with oral FLU seem to be effective for 
OM if its bone penetration appears to be limited? In 
our review (Tables 1-5), we found few reported 
failures of OM treatment, either in adults or children. 
Likewise, in the study by Vinod et al., of 32 children 
with OM treated with IV FLU for a median of three 
days, followed by oral therapy for a median of 6 
weeks, the relapse rate was only 1.4% (20). We can 
only speculate on the reasons. Based on our review 
and personal communications, even in “oral 
FLU-supporting countries” (44-46), treatment of acute 
as well as chronic OM is almost always started with 
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intravenous FLU for about two weeks, which is then 
followed by a longer period of oral FLU. Official 
guidelines in Australia (43,46) have been 
recommending a much longer intravenous duration 
for OM compared to what is currently in place in 
Switzerland (~ 2 weeks or less). It is possible that long 
oral maintenance antibiotic therapy is unnecessary, as 
an unimpaired immune system is able to eradicate the 
remaining bacteria (1,41), including for DFO 
(44,45,52). This is why in this review we elected to 
circumvent the confounding bias of long duration 
intravenous therapy by targeted OM episodes in 
which ≥ 50% of the course was with oral FLU.  
There is more data supporting the clinical 
efficacy in treating OM in various settings with oral 
β-lactams other than FLU. For example, many experts 
in the Nordic countries consider cloxacillin (which is 
not FLU, sensu strictu) the preferred oral β-lactam 
drug. For example, Bachur et al. found good outcomes 
with a four-day intravenous administration of 
cefazolin with an early switch to oral cephalexin for 28 
days in stable OM (65). Similarly, Le Saux found no 
superiority for a long-duration intravenous β-lactam 
administration in children with hematogenous OM 
(66) compared to a short duration. Likewise, Zaoutis 
et al. in a retrospective study of hematogenous 
pediatric OM, treatment with prolonged intravenous 
β-lactam therapy compared to an early switch to oral 
therapy gave similar outcomes at six months (67). 
Several pediatric studies in the 1970s and 1980s 
summarized the feasibility of oral β-lactam care for 
OM (11). The recently published OVIVA trial 
prospectively randomized various types of sever bone 
and joint infections, including infected arthroplasties 
and osteomyelitis, into either six weeks of intravenous 
antibiotic therapy or a switch to oral antimicrobials 
after up to 7-days of initial parenteral therapy (7). 
Roughly 38% of all participants had infections with 
MSSA. Overall, 74 patients in the oral arm were 
treated with oral penicillins and clinical failure was 
noted in 17 (23%), compared to 9 of 57 (16%) in the 
intravenous arm, a non-significant difference (7; 
Supplementary Appendix).  
There is also a great variability in antibiotics 
used in patients with DFO, with co-amoxiclav among 
the most frequently orally administered β-lactams 
worldwide (11). In a retrospective cohort analysis of a 
clinical pathway for patients with DFO, the authors 
conducted a cluster-controlled Cox regression model 
with an emphasis on the more than 300 patients 
treated with oral co-amoxiclav (at a median dose of 
2000 mg BID/day) (11). After a median follow-up of 
three years, DFO recurred in 22% of the patients, 
which is compatible with rates reported for various 
treatments in the literature. In multivariate analysis, 
treatment with oral co-amoxiclav did not influence 
the likelihood of remission or recurrence, either when 
used as the only agent from the start, or when 
administered for >50% of the entire antibiotic course 
(11). Likewise, in a prospective trial by Lázaro- 
Martínez et al. randomizing patients with DFO to 
either primarily antibiotic treatment (24 cases with 
oral co-amoxiclav and 24 cases with other oral 
antimicrobials) for ninety days or to “conservative” 
surgery and antibiotics for 10 days (68), there were no 
significant differences in outcomes. In contrast to the 
situation with oral FLU, some international guidelines 
(49) suggest co-amoxiclav is a viable oral antibiotic 
option for treating DFO (11). These data from studies 
of other oral β-lactam agents also support the use of 
oral FLU as a possible alternative in OM. 
Our narrative review has several limitations, the 
most important of which is the heterogeneity of 
practice regarding treatment with oral FLU. 
Considering that in some countries oral FLU use is 
already firmly established and recommended in 
national guidelines (44-46), there are probably tens of 
thousands of OM cases treated each year in this way. 
Unfortunately, these clinicians have rarely published 
their experience. For this review we specifically 
avoided contacting these colleagues, in order to base 
our conclusions on internationally published reports 
and not just personal communications. One alternative 
would have been to send questionnaires to treating 
clinicians around the world. Such as task is 
time-consuming, difficult and prone to selection 
biases; we know of no exhaustive list of infectious 
diseases experts in bone and joint infections. There is a 
Philadelphia Consensus (69) group that probably 
comes closest to what we imagine of such a 
community, but it is also composed of invited persons 
identified by their academic activity; without 
representing an exhaustive list of experts. 
Conclusions 
Based only on the limited in vitro data for 
penetrating into bone, oral FLU could be seen as 
inferior to other oral agents that are not β-lactams, for 
which a bone penetration may be better. However, the 
role of antibiotic penetration, as commonly measured, 
in outcomes of treatment of bone infection is far from 
clear (70). Furthermore, most infectious diseases 
experts lack extensive personal experience in 
administering oral FLU as treatment for OM, while 
the small number who do (mostly from 
English-speaking or Northern European countries) 
have apparently not seen the need to publish their 
experience. The few published clinical studies clearly 
demonstrate that after any necessary debridement, a 
short course of intravenous FLU followed by oral FLU 
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is a safe and effective option for treating OM (perhaps 
including DFO) in adults and children.  
We encourage those who treat OM patients to 
consider conducting prospective trials, as treatment 
with oral FLU has several important advantages to 
make it worth investigating in in light of the problem 
of increasing antibiotic resistance: relatively low risk 
for adverse events and drug interactions; a narrow 
antibiotic spectrum; and, relatively low costs. 
Optimally, these studies would be randomized 
controlled trials comparing oral FLU to an oral 
quinolone. Statistically, the first option would 
probably require 2 x 232 OM episodes in a standard 
binary outcome non-inferiority trial with inferiority 
limits of 15%. Alternatively, even a prospective cohort 
study with oral FLU would be useful.  
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